BRAF and melanoma: For example, the X-ray crystallographic determination of the BRAF kinase structure revealed the molecular mechanism of its activation in melanoma, leading to the development of vemurafenib, a targeted therapy for BRAF-mutant melanoma (Long et al., 2014).